Susceptibility of <i>Yersinia enterocolitica</i> to eight β-lactam antibiotics and clavulanic acid

Gašpar, Marija; Soriano, Francisco

doi:10.1093/jac/8.2.161

Cited by 11 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Positive iodometric detection with benzylpenicillin and ampicillin as substrates, and high synergism demonstrated for clavulanic acid and sulbactam in combination with carbenicillin (decrease of MIC of seven dilution factors), suggested that most of the strains tested (106) produced at least a penicillinase-type enzyme like 1-lactamase A. This powerful synergy of clavulanic acid in combination with carbenicillin could appear contradictory to data reported on a poor potentiation effect between clavulanic acid and ampicillin against Y. enterocolitica strains (6). However, the ampicillin resistance also could be mediated by a cephalosporinasetype 3-lactamase, and clavulanic acid is less effective against this type of enzyme (19,22).…”

mentioning

confidence: 79%

In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics

Hornstein¹,

Jupeau²,

Scavizzi³

et al. 1985

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The MICs of 21 P-lactam antibiotics were measured against 126 clinically significant and epidemiologically unrelated Yersinia enterocoEltica isolates. The most active antimicrobial agents tested (geometric means of MICs) were ceftriaxone, cefotaxime, ceftizoxime, and cefmenoxime (0.06 to 0.08 ,ug/ml). Mezlocillin (1.36 ig/ml) and piperacillin (1.57 ,ug/ml) were the most active penicillins. Aztreonam (5, 8-11, 17, 21, 30, 31), and the entire species was considered to be resistant to these 1-lactam antibiotics (23). Different patterns of ,B-lactam resistance were reported according to serotype (1, 5, 9, 10, 28).Several 1-lactamases including 1-lactamases A and B were found to be produced by Y. enterocolitica strains (3-5) and associated with serotypes (3, 14). Production of 3-lactamase is a resistance mechanism which could explain the clinical inefficiency of 1-lactamase-hydrolyzable antibiotics such as ampicillin and cephalothin against Y. enterocolitica infections (15,20,25).The recent availability of newer ,B-lactam antibiotics not actually hydrolyzed by ,B-lactamases gave rise to a renewed interest for these antibiotics. Marked in vitro activity of some newer 1-lactam antibiotics against Y. enterocolitica isolates has been reported (16,24,26,29).The purposes of the present study were to (i) determine comparatively countries) and the serotype (22 0 serotypes) of the clinical isolates are given in Table 1. The isolates were stored in semisolid conservation agar (catalog no. 63683; Institut Pasteur Production, Marnes-la-Coquette, France) at room temperature in the dark. All strains were susceptible by the agar dilution method to streptomycin, kanamycin, gentamicin, tetracycline, chloramphenicol, colistin, nalidixic acid, rifampin, trimethoprim (except three strains), and sulfonamides (except four strains).Antibiotics. The 21 antibiotics of known potency used in this study were kindly supplied by the manufacturing companies (or their subsidiary agents). For the purpose of generalization, these antibiotics were classified as follows: (i) Penicillins, including the old penicillins ampicillin and carbenicillin (Beecham, Paris, France) and the newer penicillins temocillin (Beecham), piperacillin (Lederle, Oullins, France), azlocillin and mezlocillin (Bayer, Puteaux, France), and apalcillin (Laboratoire Francais de Thdrapeutique, Bordeaux, France); (ii) aztreonam (Squibb, Neuilly s/Seine, France); a monobactam antibiotic; (iii) imipenem (formerly imipemide or N-formimidoyl thienamycin), a carbapenem antibiotic (Merck, Paris, France); (iv) cephalosporins, including the first-generation cephalosporins cephalothin (Lilly, Saint Cloud, France) and cephaloridine and cephalexin (Glaxo, Paris, France), the second-generation cephalosporins cefoxitin (Merck) and cefamandole (Lilly), and the third-generation cephalosporins cefotaxime (Roussel,

show abstract

mentioning

confidence: 79%

In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics

Hornstein¹,

Jupeau²,

Scavizzi³

et al. 1985

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Επίσης ο συνδυασμός αμοξυσιλίνης και κλαβουλανικού οξέος διαπιστώθηκε ότι έχει καλά αποτελέσματα στη θεραπεία της νόσου. (Gaspar 1981).…”

Section: σπάνιες κλινικές εκδηλώσειςunclassified

Ο Ρολος Της Yersinia Enterocolitica Στην Αιτιοπαθογενεια Της Οξειας Σκωληκοειδιτιδας Και Του Χρονιου Διαρροικου Συνδρομου

Μπαρμπατζασ¹

View full text Add to dashboard Cite

Συμμετοχή σε επιστημονικές εταιρείες: 1)Είμαι μέλος της Ελληνικής Γαστρεντερολογικής Εταιρείας. 2)Είμαι μέλος της Εταιρείας Ιατρικών Σπουδών. Εκπαιδευτικό Έργο: 1) Από το 1990 μέχρι σήμερα συμμετείχα ενεργά ως εκπαιδευτής στα εκπαιδευτικά προγράμματα για τους ειδικευόμενους και ειδικευμένους ιατρούς της Γεν. ιατρικής στο Γενικό Νοσοκομείο Νίκαιας -Πειραιά. 2) Το 1995 και 1996 συμμετείχα ενεργά στο εκπαιδευτικό πρόγραμμα για τους ειδικευμένους του Γαστρεντερολογικού Τμήματος του Τζανείου * Νοσοκομείου. 3) Από το 1995 μέχρι σήμερα διδάσκω το μάθημα της Παθολογίας στη Μέση Τεχνική Σχολή Αδελφών Νοσοκόμων του Γενικού Νοσοκομείου Νίκαιας -Πειραιά.

show abstract

Diagnosis and Treatment

Butler

1983

Plague and Other Yersinia Infections

View full text Add to dashboard Cite

Susceptibility of Yersinia enterocolitica to eight β-lactam antibiotics and clavulanic acid

Cited by 11 publications

References 0 publications

In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics

In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics

Ο Ρολος Της Yersinia Enterocolitica Στην Αιτιοπαθογενεια Της Οξειας Σκωληκοειδιτιδας Και Του Χρονιου Διαρροικου Συνδρομου

Diagnosis and Treatment

Contact Info

Product

Resources

About